Functional and Quality of Life Outcomes Following Viscosupplementation for Knee Osteoarthritis
This study is currently recruiting participants.
Verified October 2012 by University of Florida
Sponsor:
University of Florida
Information provided by (Responsible Party):
University of Florida
ClinicalTrials.gov Identifier:
NCT01447303
First received: September 29, 2011
Last updated: October 22, 2012
Last verified: October 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will compare changes in outcomes following viscosupplementation for knee osteoarthritis.
| Condition | Intervention |
|---|---|
|
Knee Osteoarthritis |
Other: Subject outcomes following viscosupplementation of the knee |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Functional and Quality of Life Outcomes Following Hyaluronic Acid (HA) Viscosupplementation for Knee Osteoarthritis |
Resource links provided by NLM:
Further study details as provided by University of Florida:
Primary Outcome Measures:
- Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) [ Time Frame: Decsribes any change from baseline over a period of 12 months; the study subjects will complete the (WOMAC) Index at baseline, 1, 3, 6 and 12 months following the viscosupplementation of the knee. ] [ Designated as safety issue: No ]The (WOMAC) Index is a multidimensional, self-administered health status instrument for patients with osteoarthritis of the hip or knee. The index is a disease-specific, purpose built, high performance instrument for evaluative research in osteoarthritis clinical trials.
Secondary Outcome Measures:
- Visual Analog Scale (VAS) documentation of the level of knee pain. The (VAS) will describe the change in the level of knee pain from baseline following viscosupplementation of the knee. [ Time Frame: The study subjects will complete the (VAS) at baseline, 1, 3, 6 and 12 months following the viscosupplementation of the knee. ] [ Designated as safety issue: No ]The (VAS) responses are expressed on a ten centimeter line, with 0 representing no pain and 10 cm representing the worst pain possible. The patient places a mark across the line representing where their perceived pain lies, from no pain to severe pain; measured at rest, standing and rising from a chair.
- Medical Outcomes Short Form (SF-36); completed to describe any change in perceived Quality of Life (QOL) from baseline following viscosupplementation of the knee. [ Time Frame: The study subjects will complete the (SF-36) at baseline, 1, 3, 6 and 12 mos. following viscosupplementation of the knee. ] [ Designated as safety issue: No ]The (SF-36) is a validated, internationally recognized standard instrument for assessing perceived (QOL) will be used to assess overall (QOL)
- Chair Rise Time; describes any change from baseline in time to rise from a chair following viscosupplementation of the knee [ Time Frame: The study subjects will complete the chair rise at baseline, 1, 3,6 and 12 mos. following viscosupplementation of the knee. ] [ Designated as safety issue: No ]Chair rise time is measured as the time required to move from a sitting position to fully standing. The measure will be repeated three times with the fastest time being recorded.
- Stair Climb Time; describes any change in the time from baseline to walk up a flight of 12 steps following viscosupplementation of the knee [ Time Frame: The study subjects will complete the stair climb at baseline, 1, 3, 6 and 12 mos. following viscosupplementation of the knee. ] [ Designated as safety issue: No ]The time to walk up one flight of stairs was measured by having the study subjects walk up one flight of stairs consisting of 12 steps as quickly as possible. This test will be repeated after a 2 to 3 minute rest, and the faster of the two trials will be used for data analysis.
- Six Minute Walk Test; describes any change from baseline in leg pain following viscosupplementation of the knee. [ Time Frame: The study subjects will complete the six minute walk test at baseline, 1, 3, 6 and 12 mos. following viscosupplementation of the knee. ] [ Designated as safety issue: No ]The study subjects will walk at a self-selected pace around a pre-measured loop for a period of six minutes. Leg pain symptoms and scores will be collected using the (VAS) scale at one minute intervals. Leg pain location and type will be noted using a leg pain diagram and a subjective list of terms to describe the pain.
- Gait Analysis; describes any changes in gait from baseline following viscosupplementation of the knee. [ Time Frame: The study subjects will complete the gait analysis at baseline, 1, 3, 6 and 12 mos. following viscosupplementation of the knee. ] [ Designated as safety issue: No ]The study subjects will walk across a 26 foot long portable walkway. The mat is filled with pressure sensors and the output is fed into a software program. The stride length and frequency, the motion of the center of mass moving over the mat and the foot pressures with the walking steps will be collected.
| Estimated Enrollment: | 200 |
| Study Start Date: | August 2009 |
| Estimated Study Completion Date: | August 2015 |
| Estimated Primary Completion Date: | August 2015 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Outcomes following viscosupplemantation
Patients with documented knee osteoarthritis receiving viscosupplementation of the knee.
|
Other: Subject outcomes following viscosupplementation of the knee
The study subject outcomes (WOMAC, VAS, SF-36, Chair rise, Stair climb, Six minute walk and Gait analysis) measured at 1, 3, 6 and 12 months following viscosupplementation of the knee
|
Detailed Description:
The specific aims of this study are to compare the changes in knee pain symptoms, physical function, gait parameters and quality of life in persons with knee OA following a standard viscosupplementation injection series of hyaluronic acid (HA) over a one year period.
Eligibility| Ages Eligible for Study: | 21 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Patients with symptomatic knee osteoarthritis.
Criteria
Inclusion Criteria:
- 21 years of age or older
- osteoarthritis degeneration, degenerative joint disease or degeneration
- fully cognizant of study procedures
- willing to carefully participate in all study processes and assessments
Exclusion Criteria:
- less that 21 years of age
- allergic reactivity to hyaluronic acid
- current knee infection, infection around injection site or any skin disease
- pregnancy or lactation
- non-ambulatory
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01447303
Contacts
| Contact: Heather K Vincent, Ph.D. | (352) 273-7459 | vincehk@ortho.ufl.edu |
| Contact: Cindy M Montero, MS | 352-273-8453 | montec@ortho.ufl.edu |
Locations
| United States, Florida | |
| UF&Shands Orthopaedics and Sports Medicine Institute | Recruiting |
| Gainesville, Florida, United States, 32607 | |
| Contact: Heather K Vincent, Ph.D. 352-273-7459 vincehk@ortho.ufl.edu | |
| Principal Investigator: Heather K Vincent, Ph.D. | |
Sponsors and Collaborators
University of Florida
Investigators
| Principal Investigator: | Heather K Vincent, Ph.D. | University of Florida Department of Orthopaedics and Rehabilitation |
More Information
No publications provided
| Responsible Party: | University of Florida |
| ClinicalTrials.gov Identifier: | NCT01447303 History of Changes |
| Other Study ID Numbers: | 293-2009 |
| Study First Received: | September 29, 2011 |
| Last Updated: | October 22, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Florida:
|
knee osteoarthritis hyaluronic acid viscosupplementation |
Additional relevant MeSH terms:
|
Osteoarthritis Osteoarthritis, Knee Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases |
Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 16, 2013